US › Healthcare

Oncolytics Biotech Inc (ONCY)

US · Healthcare · Biotechnology

$0.81+4.58%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-12.9M
Profit YoY
-92.8%
EPS
$-0.11
EPS estimate
$-0.07

EPS came in at -0.11 against a street estimate of -0.07 — a miss of 57.1%.

Key statistics

Market cap
$89.9M
Forward P/E
45.5
P/B
1,055.04
Book value
$-0.04
EPS (TTM)
$-0.32
52-week high
$1.51
52-week low
$0.73
50-day MA
$0.87
200-day MA
$0.97
Beta
1.09

Analyst view

Analysts rate Oncolytics Biotech Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $5.08.

Shareholding

Insiders
2.19%
Institutions
3.40%

Largest institutional holders

FundStake
Marshall Wace Asset Management Ltd0.72%
Renaissance Technologies Corp0.60%
Sandbox Financial Partners, LLC0.34%
SEEDS INVESTOR LLC0.22%
Tocqueville Asset Management L.P.0.12%
Everhart Financial Group, Inc.0.12%
PFG Investments, LLC0.11%
XTX Topco Ltd0.09%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Oncolytics Biotech Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.